Enhance your nephrology practice with CME and tools focused on kidney medicine.
Unmasking IgAN: From Suspicion to Timely Diagnosis
Jörg Latus, MD
Chee Kay Cheung, MBCHB, MRCP, PHD
Advances in IgAN Care From Kidney Week
Sydney Tang, MBBS, MD
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
Jürgen Floege, MD
Jonathan Barratt, PhD
Current Experiences in Identifying and Treating Itch in Patients on Hemodialysis
James Burton, DM, FRCP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
David Wheeler, MB, CHB, MD, FRCP
Managing Symptom Clusters in Patients on Hemodialysis With CKD-aP
Kelly Chenlei Li, MBBS, FRACP
Paul Bennett, RN, MHSM, PhD, FISN
Thilo Krüger, MD, PhD
Call to Action: Utilizing Avacopan to Improve AAV Care
Stephen McAdoo, MD
Overcoming Clinical Inertia in Hyperkalemia Management
Peter Rossing, MD, DMSc
Michael Böhm, MD, FESC
Luca De Nicola, MD, PhD
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
Unveiling the Latest Advancements in CKD-Associated Pruritus Care
Stefan H. Jacobson, MD, PhD
Carlos Narváez Mejía, MD
Curbside Consult: Optimizing IgAN Management
Khalil El Karoui, MD
Federico Alberici, MD, PhD
Getting to the Root of CKD-Associated Pruritus: Questions From the Field
Joel Topf, MD
Incorporación de terapias dirigidas en la planificación del tratamiento de la VAA
David Jayne, MD
Bernhard Hellmich, MD
Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
Jay Reddy, MD, FASN
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Steven Fishbane, MD
Lucio Manenti, MD, PhD
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
No Patient Left Behind! Advancing CKD-Associated Pruritus Care
Kieran McCafferty, MD
Maurizio Gallieni, MD
Advancing IgAN Care: Expert Strategies for Transformative Patient Outcomes
Jurgen Floege MD
Uyen Huynh-Do, MD
Understanding the Recent Advances in IgAN
Incorporating Targeted Therapies in Treatment Planning for AAV
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Separating Fact from Fiction: The Realities of CKD-aP
Antoine Lanot, MD, PhD
Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease
Mario Cozzolino, MD, PhD
Jan T. Kielstein, MD, FASN, FERA
Updates in Glomerular Disease
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.